Literature DB >> 12646975

Association of ovarian tumor epithelium coexpressing HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes.

Norihiro Matsushita1, Mohammad Ghazizadeh, Hideki Konishi, Tsutomu Araki.   

Abstract

Understanding of the relationship between tumor infiltrating cytotoxic T lymphocytes (CD 8(+)TILs) and tumor cells as well as tumor-associated antigens is important and may reflect the extent of immune response of the patient to the tumor, thus providing a useful clue relevant to the prognosis. The purpose of this study was to determine the relationship between the expression of HLA-DR and CA-125 antigens and the presence of CD 8(+)TILs with regard to the established clinicopathological factors of ovarian carcinomas using immunohistochemical methods. Thirty-one ovarian carcinomas consisting of 20 serous, 7 mucinous, and 4 clear cell types were examined. Of these, 18 (58%) and 22 (71%) were positive for HLA-DR and CA-125 antigens respectively, and the overall mean number of the CD 8(+)TILs was 7.2+/-2.9. A significant association was observed between the mean number of CD8(+)TILs and tumor grade (P=0.01), disease stage (P=0.003), and patient outcome (P=0.01). The mean number of CD 8(+)TILs in HLA-DR positive (8.6+/-2.2) or CA-125 positive (8.4+/-2.1) tumors was significantly higher than that in HLA-DR negative (5.2+/-2.5; P=0.0003) or CA-125 negative (4.2+/-2.2; P=0.00002) tumors. These significant levels were further enhanced by one order of magnitude when the mean number of CD 8(+)TILs in tumors positive for both HLA-DR and CA-125 antigens (9.1+/-1.7) was compared to that in HLA-DR negative or CA-125 negative tumors. The frequency of cancer-related deaths in HLA-DR and CA-125 positive tumors was significantly lower than in the negative tumors (P=0.01). These data suggest that concurrent expression of HLA-DR and CA-125 antigens may augment the immune response of the patient to the tumor, thus providing a potential clue relevant to the prognosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12646975     DOI: 10.1272/jnms.70.40

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  8 in total

Review 1.  Tumor infiltrating lymphocytes in ovarian cancer.

Authors:  Phillip P Santoiemma; Daniel J Powell
Journal:  Cancer Biol Ther       Date:  2015-04-20       Impact factor: 4.742

2.  Enumeration of leukocyte infiltration in solid tumors by confocal laser scanning microscopy.

Authors:  J Biggerstaff; B Weidow; A Amirkhosravi; J L Francis
Journal:  BMC Immunol       Date:  2006-07-21       Impact factor: 3.615

3.  Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-gamma in promyelocytic cells.

Authors:  Andrea De Lerma Barbaro; Alessandro De Ambrosis; Barbara Banelli; Giuseppina Li Pira; Ottavia Aresu; Massimo Romani; Silvano Ferrini; Roberto S Accolla
Journal:  Int Immunol       Date:  2008-10-01       Impact factor: 4.823

4.  Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Authors:  Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson
Journal:  PLoS One       Date:  2009-07-29       Impact factor: 3.240

5.  Role of gene methylation in antitumor immune response: implication for tumor progression.

Authors:  Alfonso Serrano; Isabel Castro-Vega; Maximino Redondo
Journal:  Cancers (Basel)       Date:  2011-03-29       Impact factor: 6.639

Review 6.  The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.

Authors:  Galaxia M Rodriguez; Kristianne J C Galpin; Curtis W McCloskey; Barbara C Vanderhyden
Journal:  Cancers (Basel)       Date:  2018-07-24       Impact factor: 6.639

7.  The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.

Authors:  Xinxin Zhu; Ling Zhao; Jinghe Lang
Journal:  Int J Gynecol Cancer       Date:  2018-10       Impact factor: 3.437

8.  Neoadjuvant chemotherapy alters the balance of effector to suppressor immune cells in advanced ovarian cancer.

Authors:  Alexandra Leary; Catherine Genestie; Félix Blanc-Durand; Sébastien Gouy; Ariane Dunant; Amandine Maulard; Françoise Drusch; Bianca Cheaib; Judith Michels; Enrica Bentivegna; Audrey LeFormal; Soizick Mesnage; Philippe Morice; Patricia Pautier; Aya S Khairallah
Journal:  Cancer Immunol Immunother       Date:  2020-08-27       Impact factor: 6.968

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.